Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 8, 2010, Pages 1657-1664

  Corsetti, James P ^a   Ryan, Dan ^a   Rainwater, David L ^c   Moss, Arthur J ^b   Zareba, Wojciech ^b   Sparks, Charles E ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

atherosclerosis; cholesteryl ester transfer protein; epidemiology; inflammation; lipoproteins; risk factors

Indexed keywords

AMYLOID A PROTEIN; C REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPASE A2;

ADULT; ALLELE; ARTICLE; CLINICAL EXAMINATION; CORONARY RISK; DNA POLYMORPHISM; FEMALE; GENE MAPPING; GENETIC MARKER; GENOTYPE; HEART INFARCTION; HIGH RISK PATIENT; HOMOZYGOTE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CORONARY DISEASE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHENOTYPE; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SERUM AMYLOID A PROTEIN; TIME FACTORS; UP-REGULATION;

EID: 77955155470     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.207977     Document Type: Article

References (34)

1. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA. 2007;298:786-798.
2. Joy T, Hegele RA. Is raising HDL a futile strategy for atheroprotection? Nat Rev Drug Discovery. 2008;7:143-155.
3. Corsetti JP, Zareba W, Moss AJ, Rainwater DL, Sparks CE. Elevated HDL is a risk factor for recurrent coronary events in a subgroup of non-diabetic postinfarction patients with hypercholesterolemia and inflammation. Atherosclerosis. 2006;187:191-197.
4. deGoma EM, Leeper NJ, Heidenreich PA. Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol. 2008;51:49-55.
5. van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ESG, Tikkanen MJ, Wareham NJ, Faergeman O, Olsson AG, Pedersen TR, Khaw KT, Kastelein JJP. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk. J Am Coll Cardiol. 2008;51:634-642.
6. van Acker BAC, Botma GJ, Zwinderman AH, Kuivenhoven JA, Dallinga-Thie GM, Sijbrands EJG, Boer JMA, Seidell JC, Jukema JW, Kastelein JJP, Jansen H, Verhoeven AJM. High HDL-C does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants. Atherosclerosis. 2008; 200:161-167.
7. Corsetti JP, Ryan D, Moss AJ, Zareba W, Sparks CE. NAD(P)H oxidase polymorphism (C242T) and high HDL-C associate with recurrent coronary events in post infarction patients. Atherosclerosis. 2007;196: 461-468.
8. Corsetti JP, Gansevoort RT, Sparks CE, Dullaart RP. Inflammation reduces HDL protection against primary cardiac risk. Eur J Clin Invest. 2010;In press.
9. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006;58:342-374.
10. Rocha V, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009;6:399-409.
11. Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Salcheen D, Dullaart RPF, Keavney B, Ye Z, Danesh J. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299:2777-2788.
12. Dullaart RPF, Sluiter W. Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis. Pharmacogenomics. 2008;9:747-763.
13. Masson D, Jiang XC, Lagrost L, Tall AR. The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. J Lipid Res. 2009;50:S201-S206.
14. Boekholdt SM, Thompson JF. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J Lipid Res. 2003;44:1080-1093.
15. Sofat R, Hingorani AD, Smeeth L, Humphries SE, Talmud PJ, Cooper J, Shah T, Dandhu MS, Ricketts SL, Boekholdt M, Wareham N, Khaw KT, Kumari M, Kivimaki M, Marmot M, Asselbergs FW, van der Harst P, Dullaart RPF, Navis G, van Veldhuisen DJ, Van Gilst WH, Thompson JF, McCaskie P, Palmer LJ, Arca M, Quagliarini F, Gaudio C, Cambien F, Nicaud V, Poirer O, Gudnason V, Isaacs A, Witteman JCM, van Duijn CM, Pencina M, Vasan RS, D'Agostino RB, Ordovas J, Li TY, Kakko S, Kauma H, Savolainen MJ, Kesaniemi YA, Sandhofer A, Paulweber B, Sorli JV, Goto A, Yokoyama S, Okumura K, Horne BD, Packard C, Freeman D, Ford I, Sattar N, McCormack V, Lawlor DA, Ebrahim S, Smith GD, Kastelein JJP, Deanfield J, Casas JP. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation. 2010; 121:52-62.
16. Corsetti JP, Zareba W, Moss AJ, Sparks CE. Serum glucose and triglyc-eride determine high-risk subgroups in non-diabetic postinfarction patients. Atherosclerosis. 2005;183:293-300.
17. 2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem. 2006;52: 1331-1338.
18. Rainwater DL. Electrophoretic separation of LDL and HDL subclasses. Methods Mol Biol. 1998;110:137-151.
19. Goldenberg I, Moss AJ, Block R, Ryan D, Corsetti JP, McNitt S, Eberly SW, Zareba W. Polymorphism in the cholesteryl ester transfer protein gene and the risk of early onset myocardial infarction among cigarette smokers. Ann Noninvasive Electrocardiol. 2007;12:364-374.
20. Corsetti JP, Ryan D, Moss AJ, Rainwater DL, Zareba W, Sparks CE. Plasminogen activator inhibitor-1 polymorphism (4G/5G) predicts recurrence in nonhyperlipidemic postinfarction patients. Arterioscler Thromb Vasc Biol. 2008;28:548-554.
21. 2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta. 2009;1791:327-338.
22. Tall AR. CETP inhibitors to increase HDL cholesterol levels. N Engl J Med. 2007;356:1364-1366.
23. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM; ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304-1316.
24. Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML; RADIANCE 1 Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620-1630.
25. Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ; RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomized, double-blind trial. Lancet. 2007;370:153-160.
26. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122.
27. Norata GD, Pirillo A, Catapano AL. Modified HDL: biological and physiopathological consequences. Nutr Metabol Cardiovasc Dis. 2006; 16:371-386.
28. Ansell BJ, Fonarow GC, Fogelman AM. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol. 2007;18:427-434.
29. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. J Clin Invest. 1995;96:2758-2767.
30. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol. 2008;23: 370-378.
31. Chait A, Han CY, Oram JF, Heinecke JW. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res. 2005;46:389-403.
32. van der Westhuyzen DR, Cai L, de Beer MC, de Beer FC. Serum amyloid A promotes cholesterol efflux mediated by scavenger receptor B-1. J Biol Chem. 2005;280:35890-35895.
33. O'Brien KD, Chait A. Serum amyloid A: the "other" inflammatory protein. Curr Atheroscler Rep. 2006;8:62-68.
34. van der Westhuyzen DR, de Beer FC, Webb NR. HDL cholesterol transport during inflammation. Curr Opin Lipidol. 2007;18:147-151.